Summary of PureTech Health Q4 2025 Earnings Call

1Key Financial Results and Metrics

Cash Position: PureTech ended 2025 with cash and cash equivalents of $277.1 million, down from $366.8 million in 2024. As of March 31, 2026, cash and cash equivalents were approximately $248.1 million.

Revenue: Consolidated revenues were $4.7 million in 2025, slightly down from $4.8 million in 2024.

Operating Loss: The operating loss decreased to $98.5 million in 2025 from $136.1 million in 2024, mainly due to reduced general and administrative expenses following the deconsolidation of Seaport.

Net Loss: Reported a net loss of $110.1 million in 2025, compared to a net income of $27.8 million in 2024, largely due to the absence of a one-time gain from the Seaport deconsolidation.

2Strategic Updates and Business Highlights

Refined Strategy: PureTech is focusing on a leaner operational model and plans to delist from NASDAQ to reduce costs. The company aims to launch founded entities earlier in the development cycle to improve capital efficiency.

Clinical Progress: Celea Therapeutics is advancing deupirfenidone for idiopathic pulmonary fibrosis (IPF), with a Phase III trial expected to commence after securing funding. Gallop Oncology reported positive Phase Ib trial results for LYT-200 in high-risk myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML).

Innovation Focus: The company plans to generate up to two development candidates over the next three years, emphasizing validated pharmacology and capital-efficient innovation.

3Forward Guidance and Outlook

Cash Runway: The company expects to maintain an operational runway through at least the end of 2028, assuming no significant realizations from founded entities.

Funding Plans: PureTech is targeting significant external capital for Celea and Gallop, with a focus on minimizing dilution while maintaining equity stakes in founded entities.

Capital Returns: The company intends to return a greater proportion of future cash generation to shareholders, particularly in the event of outsized returns.

4Bad News, Challenges, or Points of Concern

Declining Metrics: The decrease in cash reserves and revenues raises concerns about the company’s financial health and ability to fund operations without relying on realizations.

Competitive Pressures: The IPF landscape is becoming increasingly competitive, which could impact Celea's ability to secure funding and market share.

Market Valuation: There is a perceived disconnect between PureTech's intrinsic value and current market valuation, which could hinder future fundraising efforts.

5Notable Q&A Insights

Cash Guidance Clarification: Management confirmed that cash runway guidance includes commitments for upcoming fundraises and does not factor in realizations from founded entities.

Funding Partner Profile: Discussions for Celea's funding are progressing well, with a majority of capital expected from external partners.

Clinical Focus: The decision to prioritize MDS over AML for LYT-200 was based on compelling clinical data and a less competitive landscape for patient recruitment.

Seaport IPO: PureTech does not plan to take board seats post-IPO for founded entities, maintaining a strategy of retaining significant equity stakes while allowing for diversification of shareholder registers. This summary encapsulates the key points from the earnings call, providing a clear overview of PureTech Health's financial performance, strategic direction, and market challenges.